<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">RETEPLASE RECOMBINANT</span><br/>(re'te-plase)<br/><span class="topboxtradename">Retavase<br/></span><b>Classifications:</b> <span class="classification">blood formers, coagulators, and anticoagulants</span>; <span class="classification">anticoagulant agent</span>; <span class="classification">thrombolytic enzyme</span><br/><b>Prototype: </b>Alteplase<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10.8 IU vials</p>
<h1><a name="action">Actions</a></h1>
<p>DNA recombinant human tissue-type plasminogen activator (TPA) that acts as a catalyst in the cleavage of plasminogen to plasmin.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Forms plasmin; responsible for degrading the fibrin matrix of the clot, and thus has antithrombolytic properties.</p>
<h1><a name="uses">Uses</a></h1>
<p>Thrombolysis management of acute MI to reduce the incidence of CHF and mortality.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Active internal bleeding, history of CVA, recent neurologic surgery or trauma, intercranial neoplasm, or aneurysm, bleeding
         disorders, severe uncontrolled hypertension.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Pregnancy (category C), lactation; any condition in which bleeding constitutes a significant hazard (i.e., severe hepatic
         or renal disease, CVA, hypertension, acute pancreatitis, septic thrombophlebitis). Safety and efficacy in children are not
         established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Thrombolysis during Acute MI</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 10 U injected over 2 min. Repeat dose in 30 min (20 U total)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Reconstitute using only the diluent, syringe, needle, and dispensing pin provided with reteplase. Withdraw diluent with syringe
                  provided. Remove needle from syringe, replace with dispensing pin and transfer diluent to vial of reteplase. Leave pin and
                  syringe in place in vial and swirl to dissolve. Do <small>NOT</small> shake. When completely dissolved, remove 10 mL solution, replace dispensing pin with a 20-gauge needle.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Flush IV line before &amp; after with 30 mL NS or D5W and do <small>NOT</small> give any other drug simultaneously through the same IV line. Give a single dose evenly over 2 min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Heparin.</b>
<span class="incompattype"> Y-site:</span>
<b>Heparin.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store drug kit unopened at 2°25° C (36°77° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Hematologic:</span>
<span class="speceff-both">Hemorrhage</span> (including <span class="speceff-both">intracranial</span>, GI, genitourinary), anemia. <span class="typehead">CV:</span> Reperfusion arrhythmias. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Causes decreases in plasminogen and fibrinogen, making coagulation and fibrinolytic tests unreliable.</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Aspirin,</b>
<b>abciximab,</b>
<b>dipyridamole,</b>
<b>heparin</b> may increase risk of bleeding. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 1316 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Discontinue concomitant heparin immediately if serious bleeding not controllable by local pressure occurs and, if not already
            given, withhold the second reteplase bolus.
         </li>
<li>Monitor carefully all potential bleeding sites; monitor for S&amp;S of internal hemorrhage (e.g., GI, GU, intracranial, retroperitoneal,
            pulmonary).
         </li>
<li>Monitor carefully cardiac status for arrhythmias associated with reperfusion.</li>
<li>Avoid invasive procedures, arterial and venous punctures, IM injections, and nonessential handling of the patient during reteplase
            therapy.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report changes in consciousness or signs of bleeding to physician immediately.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>